Fengzhi Li

Dr. Li is the founder and Chief Scientific Officer (CSO) of the Canget BioTekpharma company. The research in his academic laboratory has been supported by federal agencies (NIH/NCI, DOD) and various public/private foundations. Dr. Li has been initially involved in the characterization of the antiapoptotic survivin gene and is one of the top leading scientists in the survivin research field. In the past decade, he has developed an outstanding scientific career and published over 50 peer-reviewed articles in the drug resistance and anti-apoptosis cancer research field relevant to the inhibitor of apoptosis (IAP) and Bcl-2 family proteins. He was reported to be in the top 5% of cited authors for the Journals relevant to Biology and Biochemistry. Dr. Li has been on the review panel list for the James and Esther King Biomedical Research Program of the Florida Department of Health to review both Technology Transfer/Commercialization Partnership Grants and Novel Cancer Therapeutics Grants from 2010. Dr. Li is also a grant reviewer for a number of countries including the United States, Singapore, UK, Israel, Ireland, and Hong Kong of China. He is also an ad hoc reviewer for many scientific journals including Cancer Research, Clinical Cancer Research, Oncogene, British Journal of Cancer, Mol Cancer Therapeutics, Clinical Chemistry, Journal of Biological Chemistry, Molecular Cancer Research, Apoptosis, BMC Cancer, Journal of Cellular Physiology, Current Cancer Therapy Reviews, Current Cancer Drug Targets, J Cell & Mol Medicine, Mol Biol of the Cell, Curr Medicinal Chemistry, Cancer Immunology Immunotherapy and PLoS ONE. He is an editorial board member on several scientific journals including Journal of Experimental & Clinical Cancer Research, American Journal of Translational Research and International Journal of Clinical and Experimental Medicine. He is also a member of a number of scientific societies including American Society for Biochemistry and Molecular Biology (ASBMB), American Association for the Advancement of Science (AAAS), American Association for Cancer Research (AACR) and the New York Academy of Sciences (NYAS). He has published over 80 peer-review articles with a total citation over 12,000 times.